Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. Could you give us an overview of the Lineage platform?

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

NOVEMBER 27, 2023

In cancer, the eIF4F complex becomes dysregulated, leading to the excessive production of these proteins, which contribute to tumour formation and resistance to treatment. How do STRIs differ from traditional cancer therapies, and what advantages do they bring? That second hurdle is translation initiation, activated by eIF4F.

Molecular Biology 86

Molecular Biology Therapies Pharmaceuticals Treatment 86

Drug Target Review

FEBRUARY 19, 2024

I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecular biology. Biochemistry and molecular biology fascinated me in school. Can you tell us about your journey in the field of STEM and the challenges you encountered along the way?

Molecular Biology 110

Molecular Biology Science Protein Expression Production 110

Broad Institute

JUNE 21, 2023

Now, researchers at the Broad Institute of MIT and Harvard have found that treatment with continuous hypoxia — low-oxygen conditions comparable to levels at a Mount Everest base camp — restores balance and coordination in a mouse model of Friedreich’s ataxia. A few treatments stood out.

Treatment 98

Treatment Disease Molecular Biology Medical Schools 98

Drug Target Review

JULY 1, 2024

As a non-opioid, SRP-001 also eliminates abuse potential, positioning it as a safer and effective drug candidate for the treatment of acute and neuropathic pain and migraine headache. Could you elaborate on the potential market size for SRP-001 and how it fits into the broader landscape of pain therapies? South Rampart Pharma, Inc.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

Alta Sciences

MARCH 1, 2024

Norbert Makori and Pierre Jolicoeur: The Benefits of Combining Preclinical and Bioanalytical for Your Gene Therapy Studies pmjackson Fri, 03/01/2024 - 22:20 Recent advances in gene therapy have allowed for diseases to be approached differently. q: How can Altasciences support sponsors’ Gene Therapy Programs?

Therapies 52

Therapies Laboratories Molecular Biology RNA 52

Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. Organoids for cell therapy and drug discovery. Stem cell-derived organoids and their application for medical research and patient treatment.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

Drug Target Review

FEBRUARY 26, 2024

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59

Drug Target Review

MAY 27, 2024

What role do ADCs play in Caris’ strategy for targeted cancer therapy, particularly in terms of patient-specific treatment plans? At a base-layer, Caris’ comprehensive molecular profiling that we perform for patients today can identify predictive biomarkers for current FDA-approved ADCs.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

Drug Target Review

AUGUST 29, 2023

The implication of this work is that we have an unprecedented opportunity to advance a single tRNA medicine to unify treatment across a wide range of diseases with the same underlying genetic mutation, enabling us to provide medicines to patients, especially those with rare or ultra-rare diseases, with no or limited treatment options.

Science 98

Science Disease Molecular Biology Therapies 98

The Pharma Data

NOVEMBER 23, 2020

Legend was launched to expand GenScript’s capabilities of developing a broad range of immunotherapy treatments. Two years after its founding, Legend Biotech tied up with Johnson & Johnson to develop the anti-BCMA CAR-T therapy ciltacabtagene autoleucel (cilta-cel). Cilta-cel snagged Breakthrough Therapy Designation from the U.S.

Government 52

Government Molecular Biology Regulations Laboratories 52

The Pharma Data

FEBRUARY 25, 2022

. “The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecular biology, Penn State. 25) in the journal Communications Biology.

FDA Approval 52

FDA Approval FDA Molecular Biology Virus 52

Broad Institute

JANUARY 30, 2024

In others, an infection can cause the immune system to spin out of control, leading to sepsis — organ dysfunction that lacks effective treatments and is often fatal. In 2005, Bhattacharyya completed PhD studies at the University of California, San Francisco, in biochemistry and molecular biology, followed by two years of medical training.

Hospitals 137

Hospitals Virus Medical Schools Science 137

Drug Target Review

OCTOBER 25, 2024

How does precision neuroscience differ from traditional approaches in the treatment of neurodegenerative diseases, and what advantages does it offer? What role do large biofluids proteomics datasets play in characterising the molecular processes that drive disease progression?

Disease 59

Disease Clinical Trials Therapies Science 59

Drug Target Review

APRIL 8, 2024

How have recent advancements in immune checkpoint blockade therapy affected outcomes for primary NSCLC? Dr Govindan : Even though immunotherapy and chemotherapy given after surgery improve the overall survival, as Dr Cote said, many may not need those therapies and a good number of them recur despite post operative systemic therapies.

Hospitals 52

Hospitals Therapies Clinical Trials Molecular Biology 52

The Pharma Data

JANUARY 6, 2021

Ichtchenko’s hypothesis that the C1 ad delivery vehicle previously reported could be used to transport therapeutic proteins into the neuronal cytosol, researchers led by Dr. Ichtchenko developed and tested a potential treatment for botulism based on intracellular inhibition of the BoNT subtype A1 light chain metalloprotease (LC/A1).

Science 52

Science Molecular Biology Treatment Production 52

The Pharma Data

SEPTEMBER 15, 2020

Amgen is a proud sponsor of MBC BioLabs, assisting high-potential and innovative early-stage life science and biotech companies accelerating development of new therapies to improve human health. We look forward to interacting with Amgen ‘s scientific and therapeutic experts to help move Trilomer® therapies into the clinic.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

The Pharma Data

NOVEMBER 18, 2021

Senior Vice President, Early Clinical Development, Hematology/ Oncology and Cell Therapy and San Francisco point head. “ Each point has a complete molecular biology core installation that allows companies to do trials on day one. A core part of our gospel is to encourage interdisciplinary collaborations and new approaches.

Molecular Biology 52

Molecular Biology Pharmaceuticals Laboratories Clinical Development 52

Codon

DECEMBER 17, 2023

Molecular biology, as the field came to be called 3 , pushed biology from an object of study, driven forward by gentleman scientists and precocious country clergymen, into a tool with which to solve urgent problems. At least six CAR-T cancer therapies have now garnered F.D.A.

Engineering 52

Engineering Molecular Biology Doctors DNA 52

The Pharma Data

SEPTEMBER 17, 2020

This is the focus of vaccines in development and convalescent plasma therapy. 6 This is being explored as an adjunctive treatment for the management of COVID-19.6 The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

Codon

MARCH 12, 2023

Related news : “More than 200 people have been treated with experimental CRISPR therapies.” The landmark paper enabled revolutions in insulin biomanufacturing, CAR-T therapies, and the bioproduction of most modern vaccines; in other words, much of what we take for granted today. Lots of gene therapy data this week.

DNA 52

DNA Engineering Therapies RNA 52

Codon

JUNE 18, 2024

Even after a half-century of molecular biology research, scientists didn’t know until recently how gas vesicles physically trap gas while occluding water. This is a large part of the reason why attempts to translate in vitro results into real-world therapies, such as medicines, often fail.

Engineering 70

Engineering Laboratories International Clinical Trials 70

Agency IQ

JANUARY 19, 2024

To start, a tissue sample is harvested and the cells of interest are isolated using method(s) such as enzymatic digestion, chemical treatment, or mechanical dissociation. This process is more thoroughly covered in guidances on gene therapy and vaccine development, and in other guidelines, such as the ICH Q5B Guideline.

Virus 40

Virus Science Production FDA 40

Drug Target Review

MAY 22, 2024

How does Circio’s circVec technology aim to enhance the potency and reduce the cost of current gold-standard gene therapy? As a first step, Circio is working on designing and validating circVec-AAV vectors for the treatment of genetic diseases, and testing these head-to-head against the mRNA-AAV equivalent in vivo.

Therapies 59

Therapies RNA Protein Expression DNA 59

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.

Licensing 52

Licensing Licensing Clinical Trials Trials 52

The Pharma Data

OCTOBER 27, 2021

He also brings experience in development of novel therapies, through his role as Founder of and Scientific Adviser to Blade Therapeutics, a biopharmaceutical company focused on disease-modifying treatments for fibrotic and neurodegenerative diseases. Dr Hal Dietz is Victor A.

Molecular Biology 52

Molecular Biology Science Medical Schools Disease 52

Drug Target Review

FEBRUARY 19, 2025

Their capacity to provide an unlimited supply of cells means that iPSCs could revolutionise cell therapies. Together, they shared valuable insights into the progress of iPSC-based therapies, the key obstacles ahead and the exciting opportunities for future breakthroughs.

Therapies 59

Therapies Molecular Biology Regulations Packaging 59

Drug Target Review

DECEMBER 12, 2024

As a result, patients receiving ESC-derived therapies must also take immunosuppressive drugs potentially for life. The process can yield a renewable stockpile of cells for everything from CAR-T cancer therapies to tissue and organ transplants. This can trigger an immune response that causes the body to reject these therapeutic cells.

Therapies 59

Therapies DNA Molecular Biology Immune Response 59

Drug Target Review

FEBRUARY 20, 2025

Throughout her career, she has focused on advancing therapeutic drug discovery and developing genetic therapies, making significant contributions to the field. One prominent project is my work using antibodies to deliver adeno-associated virus (AAV) gene therapies to targeted cells in the body.

Virus 52

Virus Therapies Molecular Biology Treatment 52

Drug Target Review

DECEMBER 9, 2024

Leading a company that develops novel therapies for complex diseases, I have navigated the challenge of securing funding, which is often more difficult for women-led companies. Traditional treatments often fall short, so we focused on a completely new approach to addressing the root causes of the disease.

Therapies 52

Therapies Disease Molecular Biology Pharmaceuticals 52

Codon

NOVEMBER 1, 2024

Amodei also imagines the ways AI could accelerate biological research and yield miraculous cures in the 21st century; everything from the prevention and treatment of nearly all infectious and inherited diseases to the elimination of most cancers. Today, a single injection of an FDA-approved gene therapy, called Hemgenix , cures this disease.

DNA 116

DNA RNA Molecular Biology Laboratories 116